Intensity Therapeutics INTS
NASDAQ INTS
$3.28 -0.01 (-0.30%)
As of: Oct 20, 2026 · 3:59 PM EDT

Intensity Therapeutics (INTS) Capital Leases (2023)

Updated

Intensity Therapeutics' Capital Leases was $144,891 in Q3 2023.

Analysis

Intensity Therapeutics (INTS) Capital Leases (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,134.42 Bn 1,103.01 Bn 19.71 Bn
2 Johnson & Johnson 619.36 Bn 537.89 Bn 17.26 Bn
3 AbbVie 510.11 Bn 483.22 Bn 12.70 Bn
4 Merck 365.37 Bn 319.75 Bn 12.21 Bn
5 Novartis Ag 297.64 Bn 261.63 Bn 11.24 Bn
6 Astrazeneca 262.52 Bn 236.21 Bn 12.86 Bn
7 Amgen 236.62 Bn 192.02 Bn 7.24 Bn
8 Gilead Sciences 192.60 Bn 166.80 Bn 6.22 Bn
9 Pfizer 170.88 Bn 117.53 Bn 10.94 Bn
10 Intensity Therapeutics 9.96 Mn -28.81 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 144,891.00
API Access

Intensity Therapeutics Capital Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-leases&ticker=INTS&period=max&api_key=YOUR_API_KEY